TFXTeleflex Incorporated
$125.11+2.9% 1Y
$125.11
$99.7952 weeks$142.09
The financials
Teleflex Incorporated by the numbers
Teleflex Incorporated (TFX) reported revenue of $570M in Q2 2026 (quarter ended Jun 30, 2026), up 29% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $100M (17% of revenue). For the full year FY2025, revenue was $1.99B (+17% year on year) and net income −$906M. Its largest product in Q2 2026 was Vascular Access at $246M, 43% of the disclosed total, ahead of Interventional at 37%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $570M | $443M | +29% |
| Gross profit | $332M | $266M | +25% |
| Operating income | $73M | $91M | −20% |
| Net income | $100M | $123M | −19% |
| Diluted EPS | $2.28 | $2.77 | −18% |
| Product | Revenue | Share |
|---|---|---|
| Vascular Access | $246M | 43% |
| Interventional | $212M | 37% |
| Surgical | $112M | 20% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $570.3M (+4.0%)
Interventional grew +86% year on yearVascular Access +9.0% year on year
Segment Latestquarter on quarteryear on year
- Vascular Access$246.3M$246.3Mquarter on quarter +4.0%year on year +9.0%+4.0%+9.0%
- Interventional$211.9M$211.9Mquarter on quarter +3.5%year on year +86%+3.5%+86%
- Surgical$112.1M$112.1Mquarter on quarter +5.0%year on year +9.1%+5.0%+9.1%
Medical Instruments & Supplies
Ranks #10 of 21 by RyuScore